Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer | Zendy

Matthew R. Smith | Zendy; Fred Saad | Zendy; Simon Chowdhury | Zendy; Stéphane Oudard | Zendy; Boris Hadaschik | Zendy; Julie N. Graff | Zendy; David Olmos | Zendy; Paul N. Mainwaring | Zendy; Ji Youl Lee | Zendy; Hiroji Uemura | Zendy; Angela LopezGitlitz | Zendy; Géralyn C. Trudel | Zendy; Byron M. Espina | Zendy; Youyi Shu | Zendy; Youn C. Park | Zendy; Wayne Rackoff | Zendy; Margaret K. Yu | Zendy; Eric J. Small | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

Author(s) -

Matthew R. Smith,

Fred Saad,

Simon Chowdhury,

Stéphane Oudard,

Boris Hadaschik,

Julie N. Graff,

David Olmos,

Paul N. Mainwaring,

Ji Youl Lee,

Hiroji Uemura,

Angela LopezGitlitz,

Géralyn C. Trudel,

Byron M. Espina,

Youyi Shu,

Youn C. Park,

Wayne Rackoff,

Margaret K. Yu,

Eric J. Small

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1715546

Subject(s) - prostate cancer , cancer , metastasis , oncology , medicine , prostate

Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer who were at high risk for the development of metastasis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research